Abstract
There is a dose-response relationship in ABC. HDC with autologous bone marrow transplantation, after conventional induction chemotherapy enhance complete response rate, but we still ignore the long term survival beneflt. Another approach is to use very HDC at induction with PBCS. We have begun a trial with epirubicin (100mg/sqm) and cyclophosphamide (3000mg/sqm) q 2 week×4. PBCS were collected after the 1st course and reinfused after course 3 and 4. As for February 1995, 12 ABC pts have received 42 courses. Relative dose-intensity was 92%. Median duration of grade 4 leukopenia lasted 3, 5, 8 and 8 days after successive courses with a median duration of fever of 3–5 d. However rehospitalization for IV antibiotics was required in less than 33% of pts. Grade 3–4 thrombocytopenia appeared after cycle 3. Other side effects were grade 0–3 and manageable. 6/18 pts achieved a PR. This treatment appears feasible and further pts will receive 6 courses. Actualized results will be presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
